by Raynovich Rod | Sep 9, 2021 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-1 Five days of selling but looks like routine re-balancing at market highs. NASDAQ leads way down 0.7% Whether it is concerns about Washington or a seasonal buyers strike or even an extended summer vacation who knows? The 3.3% drop in AAPL on App Store ruling...
by Raynovich Rod | Jul 26, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Healthcare Stocks Are Tracking Well-Indices are at Record Highs Look to Large Cap Biopharma earnings in coming weeks. Pfizer on Wednesday. Momentum in speculative small caps are lagging so may need to wait for Q4. Macro concerns lie ahead: China, Infrastructure deal...
by Raynovich Rod | May 9, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-3 11:20a 5/17. Large Caps continue to Look Good; Defensive with dividends and a little growth. ~1% movers as of mid-day trading: AZN, BIIB,GILD, GSK, REGN. IBB lags. Update-2 1:15p EDT Biotech stocks remain sluggish as NASDAQ rally slumps to red. Large caps...
by Raynovich Rod | Mar 8, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update on rally day 3/9/21 1:22p Biotech and Healthcare Movers per Post Tech stocks rally on reversal trade. Biopharma positioned between value and moderate growth. COVID Vaccine stocks all up big BNTX CVAC NVAX MRNA. Small caps continue in uptrend ; IJR IWC IWM....
by Raynovich Rod | Mar 3, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Macro
Update-1 3/5/21…2:30p-Large Cap Biopharmas Firming Up See our last Large Cap Review . IBB up 0.73% at $148 handle. Regeneron up 3% off bottom, FWD PE 11.31, P/S 5.7, 11.75 QtQ sales growth . Nice moves in AMGN, BIIB, GILD, GSK, LLY. Review your large caps!...
by Raynovich Rod | Feb 22, 2021 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-2 2/25…Correction seems more real just after market indices hit new highs yesterday: QQQ down 3.49% piercing 200 MA at $312.83. An unusual down day when both bonds and stocks take a hit over concerns about rapidly rising 10 yr TSY rates now yielding...
by Raynovich Rod | Feb 7, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-1 FEB 11, Momentum easing with some good stocks moves, XBI off 1.3% to $165.83. Coronavirus focus stocks are mixed with our holdings doing well. ABT up 1.24%, HOLX up 0.53% and Genmark Diagnostics (GNMK) up 33% to $22.46 on rumors of being acquired, but...
by Raynovich Rod | Jan 25, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
1/28/21 Update-2 VIR Hits $140 yesterday then rolls over to $58+ today! JPMorgan downgraded VIR letting some of the air out of the ballon. The recent speculation may have been about a VIR antibody mirroring the therapeutic potential of the Lilly (LLY) developments....
by Raynovich Rod | Jan 1, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 Jan 5, 2021 Nice Reversal to the Upside! Energy stocks rock! NASDAQ moved up 1% and the S&P followed up 0.71% both near highs of the day. Energy stocks were a big gainer with the XLE up 4.5% and the metals ETF up 5%(XME) a new trend in materials and...
by Raynovich Rod | Dec 14, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1. 12/15…With Biden being declared a winner the focus of macro turns to stimulus talks and the FED Meeting tomorrow. The market ebullience returned today with all major indices up over 1%. The Pfizer vaccine is rolling out with Moderna expected next. With...